Orgenesis Inc (ORGS) - News Archive

On September 23, 2024, Orgenesis Inc. (Nasdaq: ORGS), a biotechnology company specializing in cell and gene therapies, announced a strategic move to enhance its stock performance by implementing a 1-for-10 reverse stock...

Orgenesis Heralds Victorious Results: A Triumph in CAR-T Therapy for CD19+ Acute Lymphoblastic Leukemia Esteemed readers of CSIMarket.com ,In a resplendent display of scientific advancement and medical prowess, Orgenesi...

In a groundbreaking announcement that is set to reverberate through the healthcare industry, Orgenesis Inc. has forged a strategic partnership with the esteemed Harley Street Healthcare Group. This alliance aims to laun...

Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership to Revolutionize Cell and Gene TherapyOrmond Beach, Florida, and Germantown, Maryland - Germfree, a leading modular cleanroom infrastructure and s...

Orgenesis Inc., a global leader in decentralized cell and gene therapies, recently announced an exciting development in the form of a definitive securities purchase agreement. In this agreement, accredited investors wil...

Orgenesis Consortium Awarded 2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP ManufacturingGERMANTOWN, Md., Feb. 29, 2024 - Orgenesis Inc. (Nasdaq:ORGS), the worl...

In a strategic move aimed at solidifying its position in the rapidly expanding field of cell and gene therapies (CGTs), Orgenesis Inc. (Nasdaq: ORGS) has recently announced its definitive agreement to acquire a 25% stak...